A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease. Monogenic lupus nephritis is distinct from non-monogenic disease with ...

The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Serum S100A8/A9 levels are “significantly higher’ among patients with cognitive impairment in systemic lupus erythematosus, and changes in S100A8/A9 correspond to changes in cognition over 1 year, ...

Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent B-cell depletion and recovery, as well as improved disease activity, said ...

Enpatoran, a TLR7/8 inhibitor, demonstrated clinically meaningful improvements in disease activity among patients with ...

Researchers from EMD Serono and global collaborators shared promising results from Cohort B of the phase II trial of the WILLOW study.

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab ...

Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis ...

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.